Adage Capital Partners Gp, L.L.C. Immuneering Corp Transaction History

Adage Capital Partners Gp, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $95,500 - $366,000	-50,000 Reduced 50.0%	50,000 $144,000
Q4 2023 Feb 14, 2024	SELL	$4.84 - $8.44 $459,800 - $801,800	-95,000 Reduced 48.72%	100,000 $735,000
Q3 2023 Nov 14, 2023	BUY	$7.21 - $10.68 $144,200 - $213,600	20,000 Added 11.43%	195,000 $1.5 Million
Q2 2023 Aug 14, 2023	SELL	$6.49 - $13.36 $194,700 - $400,800	-30,000 Reduced 14.63%	175,000 $1.77 Million
Q1 2023 May 15, 2023	BUY	$3.78 - $10.38 $491,400 - $1.35 Million	130,000 Added 173.33%	205,000 $1.99 Million
Q3 2022 Nov 14, 2022	SELL	$5.0 - $14.32 $50,000 - $143,200	-10,000 Reduced 11.76%	75,000 $1.07 Million
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $252,850 - $507,650	-65,000 Reduced 43.33%	85,000 $460,000
Q1 2022 May 16, 2022	SELL	$6.47 - $16.99 $1.06 Million - $2.79 Million	-164,000 Reduced 52.23%	150,000 $971,000
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $5.06 Million - $9.74 Million	314,000 New	314,000 $5.08 Million

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $57.8M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.